SF
CRBP icon

Synovus Financial’s Corbus Pharmaceuticals CRBP Stock Holding History

Synovus Financial’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,200
Closed -$7.29K – 844
2022
Q4 		$7.29K Buy
2,200
+1,667
+313% +$6.41K ﹤0.01% 857
2022
Q3 		$3K Hold
533
– – ﹤0.01% 842
2022
Q2 		$4K Hold
533
– – ﹤0.01% 838
2022
Q1 		$9K Hold
533
– – ﹤0.01% 841
2021
Q4 		$10K Buy
+533
New +$14.4K ﹤0.01% 853

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Synovus Financial's CRBP Position: Q1 2023 in Review

Synovus Financial sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 2,200 shares — an estimated $7.29K sold.

Synovus Financial first reported a position in CRBP in Q4 2021 and held it in 5 quarters. The position peaked at $10K in Q4 2021. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

  • Synovus Financial reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Synovus Financial sold 2,200 Corbus Pharmaceuticals shares in Q1 2023, an estimated $7.29K.
  • Synovus Financial first reported a position in Corbus Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Synovus Financial's Corbus Pharmaceuticals position peaked at $10K in Q4 2021.
  • 30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on Synovus Financial's 13F filing for Q1 2023, filed 11 May 2023.